LORBRENA (lorlatinib) 2 Contraindications

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

For Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
SelectFor Canadian
Healthcare ProfessionalsFor Canadian
Healthcare Professionals
For Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
SelectFor Canadian
Patients, Consumers or CaregiversNo, go back to the patient portal
Site is intended for Canadian residents. For Non-Canada residents click here.
  • LORBRENA (lorlatinib) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.
  • Concomitant use of strong CYP3A inducers with LORBRENA is contraindicated due to the potential for serious hepatoxicity (aspartate aminotransferase [AST] and alanine aminotransferase [ALT] elevations (see 4 DOSAGE AND ADMINISTRATION and 9 DRUG INTERACTIONS).